Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers

Area of Science:

• Gastroenterology and Pharmacology
• Acid-based disorder management

Background:

• Proton pump inhibitors (PPIs) revolutionized acid suppression in the 1980s by targeting parietal cell proton pumps.
• Potassium-competitive acid blockers (P-CABs) represent a newer class of drugs with a novel mechanism for profound and sustained acid suppression.

Purpose of the Study:

• To review the pharmacologic properties of PPIs and P-CABs.
• To analyze current literature on P-CABs, focusing on recent clinical trials in Western populations.
• To explore potential therapeutic applications of P-CABs in managing acid-related disorders.

Main Methods:

• Review of existing literature and clinical trial data for P-CABs, particularly vonoprazan.
• Focus on trials conducted in Western populations for indications such as H. pylori infection, erosive esophagitis, and nonerosive reflux disease.

Main Results:

• Recent clinical trials in Western populations demonstrate promising results for vonoprazan in treating acid-related conditions.
• Vonoprazan has received US Food and Drug Administration approval for specific indications.
• Adverse event profiles of P-CABs appear comparable to PPIs, though long-term data are still pending.

Conclusions:

• P-CABs, like vonoprazan, offer a significant advancement in acid suppression therapy.
• Further long-term studies are necessary to fully elucidate the safety and efficacy of P-CABs.
• Identifying optimal patient populations and clinical scenarios for P-CAB integration is crucial.